Veliparib
Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively[1].
Product Specifications
CAS Number
[912444-00-9]
Product Name Alternative
ABT-888
UNSPSC
12352005
Hazard Statement
H302, H317
Target
Autophagy; PARP
Type
Reference compound
Related Pathways
Autophagy; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Veliparib.html
Purity
99.77
Solubility
DMSO : ≥ 29 mg/mL
Smiles
O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N
Molecular Formula
C13H16N4O
Molecular Weight
244.30
Precautions
H302, H317
References & Citations
[1]Donawho CK, et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13 (9) :2728-37.|[2]Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22 (2) :194-201.|[3]Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PARP1; PARP2
Citation 01
Acta Pharmacol Sin. 2022 Apr;43 (4) :781-787.|Adv Sci (Weinh) . 2025 Jul 16:e15585.|Adv Sci (Weinh) . 2025 Jun 25:e02448.|Analyst. 2025 Dec 1;150 (24) :5501-5513.|Biomed Res Int. 2023 Feb 6:2023:7891753.|bioRxiv. 2025 Nov 4:2025.11.03.686423.|BMC Cancer. 2022 Mar 23;22 (1) :312.|Cancer Discov. 2017 Sep;7 (9) :984-998.|Cancer Genet. 2019 Nov:239:26-32.|Cancer Res. 2025 May 14.|Cancers (Basel) . 2024 Nov 5;16 (22) :3728.|Cancers (Basel) . 2024 Oct 10;16 (20) :3441.|Cell Death Dis. 2024 Dec 18;15 (12) :914.|Cell Signal. 2025 Jul:131:111709.|Cells. 2021 Mar 9;10 (3) :599.|Clin Cancer Res. 2017 Feb 15;23 (4) :1001-1011. |Ecotoxicol Environ Saf. 2023 Mar 1:252:114630.|EJNMMI Res. 2025 Apr 29;15 (1) :50.|Front Mol Biosci. 2021 Apr 29:8:633344.|Front Oncol. 2021 Jul 9:11:681441.|Int J Biol Macromol. 2023 Jul 1;242 (Pt 2) :124794.|J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195.|J Invest Dermatol. 2024 May 30:S0022-202X (24) 00384-1.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Transl Med. 2024 Nov 26;22 (1) :1062.|J Vet Med Sci. 2018 Nov 23;80 (11) :1775-1781. |Mol Cancer Ther. 2019 Nov;18 (11) :2063-2073.|Nanomaterials. 2021 Jun 8;11 (6) :1514.|Nat Chem Biol. 2025 Jun 27.|Nat Commun. 2021 Jun 24;12 (1) :3931.|Nature. 2025 Sep;645 (8082) :1071-1080.|Neoplasia. 2018 Mar 28;20 (5) :478-488. |Neoplasia. 2025 May:63:101152.|Neoplasia. 2019 Apr 24;21 (6) :533-544. |Oncogene. 2022 Sep;41 (37) :4271-4281.|Oncol Lett. 2025 Jan 7;29 (3) :128.|Patent. US20180263995A1.|Patent. US20180362972A1.|Res Sq. 2024 Feb 21:rs.3.rs-3970470.|Research Square Preprint. 2021 Feb.|Research Square Preprint. 2024 Nov 06.|Sci Signal. 2025 Oct 21;18 (909) :eadx2532.|Theranostics. 2020 Jul 25;10 (21) :9477-9494. |Electrostatics Joint Conference. 2016 July.|Harvard Medical School LINCS LIBRARY|Int J Curr Res Acad Rev. 2017; 5 (3) : 53-64.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Patent. US20200078369A1|Patent. US20200129476A1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
